News

Monthly Prescribing Reference1mon
Trastuzumab Deruxtecan + Pertuzumab Promising as First-Line for HER2+ Metastatic Breast Cancer
Patients treated with trastuzumab deruxtecan + pertuzumab had a statistically significant and clinically meaningful improvement in PFS compared with standard of care. Topline results were ...
The American Journal of Managed Care3mon
TROPION-Breast01: Datopotamab Deruxtecan Improves Progression-Free Survival
Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, discusses findings from the TROPION-Breast01 study on datapotamab deruxtecan for patients with HR ...
clinicaladvisor.com4mon
Enhertu Approved for HR+, HER2-Low/Ultralow Metastatic Breast Cancer
In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA ...
The American Journal of Managed Care4mon
FDA Approves Trastuzumab Deruxtecan for HER2-Low/Ultralow Breast Cancer
Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% reduction in ...
Labroots4mon
FDA approval of new drug for hormone positive breast cancer
On January 17, 2025, the Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk a Trop-2-directed antibody and topoisomerase inhibitor conjugate. This approval marks a significant ...
MedPage Today4mon
FDA Approves Datroway for Pretreated Advanced Breast Cancer
The FDA approved datopotamab deruxtecan (Datroway) for adults with unresectable or metastatic, hormone receptor (HR)-positive/HER2-negative breast cancer who have ...
Morningstar4mon
Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Review in the US for the treatment of adult ...
PharmiWeb4mon
Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
Application based on TROPION-Lung05 trial and supported by data from TROPION-Lung01 and TROPION-PanTumor01 trials Approval would mark the first for AstraZeneca and Daiichi Sankyo’s datopotamab ...
ascopubs.org4mon
Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study
Patients received Dato-DXd 6 mg/kg once every 3 weeks. The primary end point was objective response rate (ORR) by blinded independent central review. Secondary end points included duration of response ...
Pharmabiz5mon
Datopotamab deruxtecan demonstrated meaningful clinical activity in patients with previously treated advanced EGFR-mutated NSCLC in TROPION-Lung05 & TROPION-Lung01 pooled analysis
A pooled analysis of the TROPION-Lung05 phase 2 and the TROPION-Lung01 phase 3 trials showed datopotamab deruxtecan (Dato-DXd) demonstrated clinically meaningful tumour response in patients with ...
Monthly Prescribing Reference8mon
Trastuzumab Deruxtecan Under Review for HER2-Low, HER2-Ultralow Metastatic Breast Cancer
A regulatory decision is expected during the first quarter of 2025. The Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application (sBLA) for ...